This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Lin, S.-Y. G.
Right arrow Articles by Siddiqi, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, S.-Y. G.
Right arrow Articles by Siddiqi, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2009, p. 3630-3634, Vol. 47, No. 11
0095-1137/09/$08.00+0     doi:10.1128/JCM.00803-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Multicenter Evaluation of Bactec MGIT 960 System for Second-Line Drug Susceptibility Testing of Mycobacterium tuberculosis Complex {triangledown}

S.-Y. Grace Lin,1* Edward Desmond,1 Donald Bonato,2 Wendy Gross,2 and Salman Siddiqi3

Microbial Diseases Laboratory, DCDC, CID, California Department of Public Health, Richmond, California,1 Tuberculosis Reference Laboratory, Veterans Affairs Medical Center, West Haven, Connecticut,2 Becton Dickinson Diagnostic Systems, Sparks, Maryland3

Received 20 April 2009/ Returned for modification 18 June 2009/ Accepted 30 August 2009

The Bactec MGIT 960 system for testing susceptibility to second-line drugs was evaluated with 117 clinical strains in a multicenter study. The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide. The critical concentration established for levofloxacin and amikacin was 1.5 µg/ml, that established for capreomycin was 3.0 µg/ml, and that established for ethionamide was 5.0 µg/ml. The overall level of agreement between the agar proportion method and the MGIT 960 system was 96.4%, and the levels of agreement for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide. The rate of reproducibility of the drug susceptibility testing results between the participating laboratories was 99.5%.

* Corresponding author. Mailing address: Microbial Diseases Laboratory, CDPH, 850 Marina Bay Parkway, Richmond, CA 94804. Phone: (510) 412-3929. Fax: (510) 412-6099. E-mail: grace.lin{at}cdph.ca.gov

{triangledown} Published ahead of print on 9 September 2009.

Journal of Clinical Microbiology, November 2009, p. 3630-3634, Vol. 47, No. 11
0095-1137/09/$08.00+0     doi:10.1128/JCM.00803-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»